| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 40.1 | 36.3 |
| Gross profit | 16.0 | 14.1 |
| Profit before tax | 19.7 | 15.7 |
| Net income | 17.3 | 13.7 |
| EPS (diluted, $ a share) | $0.01 | $0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +26.4% |
|---|---|
| Revenue, year on year | +10.4% |
| Gross margin | 39.9% |
| Operating margin | 24.8% |
10-Q filed with the SEC, OTC: ELTP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Elite Pharmaceuticals Inc: key numbers
- Share price
- $0.3700Close, Nov 16
- Market cap
- $399M
- Shares outstanding
- 1.08BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Elite Pharmaceuticals Inc
All →Elite Pharmaceuticals Financial Results
Elite Pharmaceuticals reported financial results for its second fiscal quarter ended September 30, 2026, with revenue increasing 10.4% to $40.1 million. The growth was driven by the company's Elite label amphetamine and naltrexone product lines, leading to a 21% increase in operating income to $9.9 million.
- Term
- Q2 2027
Elite Pharmaceuticals Leadership Change
Elite Pharmaceuticals increased its Board of Directors from four to six members and appointed Dr. Aqeel A. Fatmi and John W. LaRocca as new directors. Both appointees bring extensive pharmaceutical industry experience in R&D, operations, and legal governance to the board.
Elite Pharmaceuticals Insider Barry H. Dash Buys $26K of Stock
Barry H. Dash bought 100,000 shares of Elite Pharmaceuticals Inc at $0.2598 a share, worth $26K in total on Oct 9, 2026. Shares held after the trade: 3,365,555 (+3.1%).
- Value
- $26K
- Shares
- 100,000
- Price
- $0.2598
- Holding change
- +3.1%
- Trade date
- Oct 9, 2026